All In Biotech

Drug Trial Radar · NCT05541510

Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

A Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study to Evaluate the Safety, and Efficacy of AD17002 (LTh[αK]) Intranasal Spray in Male and Female Participants Aged 18 to 65 Years With Mild to Moderate COVID 19

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

180

Actual

Start

Dec 1, 2022

Primary completion

Aug 5, 2024

Study completion Aug 25, 2024

Sponsor

Lead sponsor
Advagene Biopharma Co. Ltd.Industry
Sponsor type
Industry
Collaborators
Gadjah Mada University
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators. This study aims to evaluate the safety and effectiveness of AD17002 in treating patients with mild to moderate COVID-19. All participants will be randomly divided into 1:1:1 groups and will receive standard treatment. Additionally, participants will be given either a placebo, 20, or 40 μg of AD17002 via intranasal delivery, and clinical progress will be compared.

Conditions

  • COVID-19

Interventions

  • AD17002 + Formulation bufferBiological

    Intranasal innate immune modulator

  • PlaceboBiological

    Formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to disease improvementTime frame: [Day 1 to Day 29]
  2. Time to achieving the Patient Acceptable Symptom State (PASS)Time frame: [Day 1 to Day 29]

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • RSPI Sulianti Saroso

    Kota Jkt Utara, DKI Jakarta, Indonesia

  • RSDC Wisma Atlit

    Kota Jkt Utara, DKI Jakarta, Indonesia

  • RSA UGM

    Yogyakarta, Special Region of Yogyakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.